FDA Approves Adamis' Cheaper Alternative to EpiPen
Adamis developed a single-dose epinephrine pre-filled syringe to treat anaphylaxis.
Read More
FDA Clears AbbVie to Produce Oral Powder form of Norvir
The powder form will be more easily administered to pediatric patients, AbbVie says.
FDA Clears Orencia for Use In Children Ages 2 and Up
Previously, the drug was only approved for patients ages 6 and up.
Migraine Drug Shows Promise in Second Phase III Trial
Teva says fremanezumab showed clinically and statistically significant improvements in all endpoints.
FDA Approves Sentinel System to Guard Against TAVR-Induced Stroke
The FDA determined Sentinel is effective in capturing debris caused by TAVR.
FDA Clears Generic Version of Strattera for ADHD Treatment
The U.S. Food and Drug Administration cleared four manufacturers to produce generic versions of Strattera (atomoxetine) for ADHD.
Case Study: Debating Discontinuation of Disease-Modifying MS Therapies
Physicians debated the case of a 65-year-old woman with SPMS.
Case Study: Would You Give This MS Patient Ocrelizumab?
Physicians debated whether they would prescribe the new MS drug to a patient.
Using Daclizumab (Zinbryta), Ocrelizumab (Ocrevus) to Treat MS
An overview of the newest treatment options for the disease.
CMSC 2017: Assessing Risk Factors for Multiple Sclerosis
The genetic, environmental, and immune factors behind the disease.
CMSC 2017: Gaining a Better Understanding of Multiple Sclerosis
Physicians received an overview of the scope and severity of the disease.
Angiotensin II Effectively Treats Vasodilatory Shock, Researchers Say
A new study published by The New England Journal of Medicine shows promising results for angiotensin II for treatment-resistant vasodilatory shock.